nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—forebrain—endogenous depression	0.0214	0.0422	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—endogenous depression	0.0181	0.0357	CbGeAlD
Thalidomide—CRBN—forebrain—endogenous depression	0.018	0.0354	CbGeAlD
Thalidomide—FGFR2—brainstem—endogenous depression	0.0167	0.0328	CbGeAlD
Thalidomide—CRBN—adrenal cortex—endogenous depression	0.0166	0.0328	CbGeAlD
Thalidomide—FGFR2—forebrain—endogenous depression	0.0161	0.0317	CbGeAlD
Thalidomide—NFKB1—pituitary gland—endogenous depression	0.016	0.0316	CbGeAlD
Thalidomide—NFKB1—adrenal gland—endogenous depression	0.0143	0.0282	CbGeAlD
Thalidomide—NFKB1—thyroid gland—endogenous depression	0.0138	0.0272	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—endogenous depression	0.0136	0.0268	CbGeAlD
Thalidomide—CRBN—pituitary gland—endogenous depression	0.0134	0.0265	CbGeAlD
Thalidomide—NFKB1—endocrine gland—endogenous depression	0.0124	0.0245	CbGeAlD
Thalidomide—CRBN—adrenal gland—endogenous depression	0.012	0.0237	CbGeAlD
Thalidomide—CRBN—midbrain—endogenous depression	0.0119	0.0234	CbGeAlD
Thalidomide—NFKB1—nervous system—endogenous depression	0.0116	0.0229	CbGeAlD
Thalidomide—CRBN—thyroid gland—endogenous depression	0.0116	0.0228	CbGeAlD
Thalidomide—NFKB1—central nervous system—endogenous depression	0.0112	0.0221	CbGeAlD
Thalidomide—NFKB1—cerebellum—endogenous depression	0.0109	0.0216	CbGeAlD
Thalidomide—FGFR2—adrenal gland—endogenous depression	0.0108	0.0212	CbGeAlD
Thalidomide—CRBN—endocrine gland—endogenous depression	0.0104	0.0205	CbGeAlD
Thalidomide—FGFR2—thyroid gland—endogenous depression	0.0104	0.0205	CbGeAlD
Thalidomide—CRBN—nervous system—endogenous depression	0.00975	0.0192	CbGeAlD
Thalidomide—CRBN—central nervous system—endogenous depression	0.00938	0.0185	CbGeAlD
Thalidomide—FGFR2—endocrine gland—endogenous depression	0.00933	0.0184	CbGeAlD
Thalidomide—CRBN—cerebellum—endogenous depression	0.00917	0.0181	CbGeAlD
Thalidomide—NFKB1—brain—endogenous depression	0.00889	0.0175	CbGeAlD
Thalidomide—FGFR2—nervous system—endogenous depression	0.00873	0.0172	CbGeAlD
Thalidomide—FGFR2—central nervous system—endogenous depression	0.00841	0.0166	CbGeAlD
Thalidomide—FGFR2—cerebellum—endogenous depression	0.00822	0.0162	CbGeAlD
Thalidomide—CRBN—brain—endogenous depression	0.00745	0.0147	CbGeAlD
Thalidomide—FGFR2—brain—endogenous depression	0.00668	0.0131	CbGeAlD
Thalidomide—PTGS1—forebrain—endogenous depression	0.00511	0.0101	CbGeAlD
Thalidomide—PTGS2—forebrain—endogenous depression	0.00489	0.00963	CbGeAlD
Thalidomide—CYP2C9—cardiovascular system—endogenous depression	0.00474	0.00933	CbGeAlD
Thalidomide—PTGS2—adrenal cortex—endogenous depression	0.00453	0.00892	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—endogenous depression	0.00449	0.00884	CbGeAlD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TPH1—endogenous depression	0.00436	0.00886	CbGpPWpGaD
Thalidomide—CYP1A2—Fatty Acid Omega Oxidation—CYP2D6—endogenous depression	0.00436	0.00885	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—CRH—endogenous depression	0.00434	0.00881	CbGpPWpGaD
Thalidomide—PTGS1—cardiovascular system—endogenous depression	0.00432	0.00852	CbGeAlD
Thalidomide—CYP2C9—Xenobiotics—CYP2D6—endogenous depression	0.00427	0.00866	CbGpPWpGaD
Thalidomide—CYP1A1—Melatonin metabolism and effects—CYP2D6—endogenous depression	0.00425	0.00863	CbGpPWpGaD
Thalidomide—CYP2C19—endocrine gland—endogenous depression	0.00419	0.00826	CbGeAlD
Thalidomide—PTGS2—cardiovascular system—endogenous depression	0.00413	0.00814	CbGeAlD
Thalidomide—NFKB1—TCR Signaling Pathway—GATA3—endogenous depression	0.0041	0.00834	CbGpPWpGaD
Thalidomide—CYP2C9—Tamoxifen metabolism—CYP2D6—endogenous depression	0.0041	0.00833	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—CACNA1C—endogenous depression	0.00397	0.00807	CbGpPWpGaD
Thalidomide—PTGS1—pituitary gland—endogenous depression	0.00383	0.00754	CbGeAlD
Thalidomide—CYP1A2—thyroid gland—endogenous depression	0.00381	0.0075	CbGeAlD
Thalidomide—CYP1A1—thyroid gland—endogenous depression	0.00376	0.0074	CbGeAlD
Thalidomide—PTGS2—pituitary gland—endogenous depression	0.00366	0.00721	CbGeAlD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—WASF2—endogenous depression	0.00365	0.00742	CbGpPWpGaD
Thalidomide—CYP1A2—Xenobiotics—CYP2D6—endogenous depression	0.00365	0.0074	CbGpPWpGaD
Thalidomide—CYP2E1—adrenal gland—endogenous depression	0.00355	0.00699	CbGeAlD
Thalidomide—CYP1A2—Tamoxifen metabolism—CYP2D6—endogenous depression	0.00351	0.00712	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—WASF1—endogenous depression	0.0035	0.00711	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—CYP2D6—endogenous depression	0.00348	0.00706	CbGpPWpGaD
Thalidomide—CYP2E1—thyroid gland—endogenous depression	0.00343	0.00675	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—endogenous depression	0.00342	0.00674	CbGeAlD
Thalidomide—PTGS1—adrenal gland—endogenous depression	0.00342	0.00674	CbGeAlD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—ADM—endogenous depression	0.00341	0.00693	CbGpPWpGaD
Thalidomide—CYP1A1—endocrine gland—endogenous depression	0.00338	0.00665	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—TPH1—endogenous depression	0.00332	0.00675	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TPH2—endogenous depression	0.00331	0.00672	CbGpPWpGaD
Thalidomide—CYP3A5—endocrine gland—endogenous depression	0.0033	0.0065	CbGeAlD
Thalidomide—PTGS1—thyroid gland—endogenous depression	0.0033	0.0065	CbGeAlD
Thalidomide—PTGS2—adrenal gland—endogenous depression	0.00327	0.00644	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—endogenous depression	0.00325	0.0064	CbGeAlD
Thalidomide—PTGS2—midbrain—endogenous depression	0.00323	0.00636	CbGeAlD
Thalidomide—CYP1A1—Melatonin metabolism and effects—MAOA—endogenous depression	0.0032	0.00649	CbGpPWpGaD
Thalidomide—CYP1A1—nervous system—endogenous depression	0.00316	0.00623	CbGeAlD
Thalidomide—CYP1A1—Oxidative Stress—MAOA—endogenous depression	0.00311	0.00632	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—GATA3—endogenous depression	0.0031	0.00629	CbGpPWpGaD
Thalidomide—CYP1A2—Tryptophan metabolism—TPH1—endogenous depression	0.00309	0.00628	CbGpPWpGaD
Thalidomide—CYP2E1—endocrine gland—endogenous depression	0.00308	0.00607	CbGeAlD
Thalidomide—CYP1A1—central nervous system—endogenous depression	0.00304	0.00599	CbGeAlD
Thalidomide—CYP1A2—Estrogen metabolism—COMT—endogenous depression	0.00301	0.00611	CbGpPWpGaD
Thalidomide—PTGS1—endocrine gland—endogenous depression	0.00297	0.00584	CbGeAlD
Thalidomide—CYP2E1—nervous system—endogenous depression	0.00288	0.00568	CbGeAlD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—CRH—endogenous depression	0.00286	0.0058	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—OXT—endogenous depression	0.00286	0.0058	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—NR3C1—endogenous depression	0.00284	0.00576	CbGpPWpGaD
Thalidomide—PTGS2—endocrine gland—endogenous depression	0.00284	0.00559	CbGeAlD
Thalidomide—PTGS1—nervous system—endogenous depression	0.00278	0.00547	CbGeAlD
Thalidomide—CYP2E1—central nervous system—endogenous depression	0.00277	0.00547	CbGeAlD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR1A—endogenous depression	0.00274	0.00556	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00273	0.00555	CbGpPWpGaD
Thalidomide—CYP2E1—cerebellum—endogenous depression	0.00271	0.00534	CbGeAlD
Thalidomide—CYP1A2—Melatonin metabolism and effects—CYP2D6—endogenous depression	0.00271	0.0055	CbGpPWpGaD
Thalidomide—PTGS1—central nervous system—endogenous depression	0.00267	0.00527	CbGeAlD
Thalidomide—PTGS2—nervous system—endogenous depression	0.00265	0.00523	CbGeAlD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—GATA3—endogenous depression	0.00264	0.00537	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—SLC6A4—endogenous depression	0.00264	0.00537	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—MAOA—endogenous depression	0.00262	0.00531	CbGpPWpGaD
Thalidomide—PTGS2—central nervous system—endogenous depression	0.00256	0.00503	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—TPH2—endogenous depression	0.00252	0.00512	CbGpPWpGaD
Thalidomide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2D6—endogenous depression	0.00252	0.00511	CbGpPWpGaD
Thalidomide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2D6—endogenous depression	0.00251	0.0051	CbGpPWpGaD
Thalidomide—PTGS2—cerebellum—endogenous depression	0.0025	0.00492	CbGeAlD
Thalidomide—CYP2E1—Oxidation by Cytochrome P450—CYP2D6—endogenous depression	0.00249	0.00505	CbGpPWpGaD
Thalidomide—CYP3A5—Oxidation by Cytochrome P450—CYP2D6—endogenous depression	0.00248	0.00504	CbGpPWpGaD
Thalidomide—CYP1A1—brain—endogenous depression	0.00242	0.00476	CbGeAlD
Thalidomide—TNF—Allograft Rejection—IL10—endogenous depression	0.00241	0.00489	CbGpPWpGaD
Thalidomide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2D6—endogenous depression	0.00237	0.00482	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidation by Cytochrome P450—CYP2D6—endogenous depression	0.00234	0.00476	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—GATA3—endogenous depression	0.00233	0.00473	CbGpPWpGaD
Thalidomide—CYP2E1—brain—endogenous depression	0.0022	0.00434	CbGeAlD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—POMC—endogenous depression	0.00217	0.0044	CbGpPWpGaD
Thalidomide—PTGS1—brain—endogenous depression	0.00212	0.00418	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR1A—endogenous depression	0.00209	0.00424	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.00206	0.00418	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—BDNF—endogenous depression	0.00205	0.00416	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—GATA3—endogenous depression	0.00204	0.00415	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00204	0.00415	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—MAOA—endogenous depression	0.00204	0.00414	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00204	0.00414	CbGpPWpGaD
Thalidomide—PTGS2—brain—endogenous depression	0.00203	0.004	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—SLC6A4—endogenous depression	0.00201	0.00409	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—GATA3—endogenous depression	0.00201	0.00409	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—MAOA—endogenous depression	0.00199	0.00404	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—POMC—endogenous depression	0.00198	0.00401	CbGpPWpGaD
Thalidomide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2D6—endogenous depression	0.00194	0.00395	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00192	0.00391	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—BDNF—endogenous depression	0.00192	0.0039	CbGpPWpGaD
Thalidomide—CYP2C19—Oxidation by Cytochrome P450—CYP2D6—endogenous depression	0.00192	0.00389	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ANK3—endogenous depression	0.00187	0.00379	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL10—endogenous depression	0.00183	0.00372	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—BDNF—endogenous depression	0.00183	0.00371	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—BDNF—endogenous depression	0.00181	0.00367	CbGpPWpGaD
Thalidomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2D6—endogenous depression	0.00177	0.0036	CbGpPWpGaD
Thalidomide—CYP2C9—Oxidation by Cytochrome P450—CYP2D6—endogenous depression	0.00175	0.00355	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—NR3C1—endogenous depression	0.0017	0.00344	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—BDNF—endogenous depression	0.00163	0.00332	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR2A—endogenous depression	0.00162	0.00329	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00157	0.0032	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.00154	0.00312	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.00153	0.00311	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—MAOA—endogenous depression	0.00152	0.00308	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2D6—endogenous depression	0.00151	0.00307	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—NR3C1—endogenous depression	0.00149	0.00304	CbGpPWpGaD
Thalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP2D6—endogenous depression	0.00149	0.00303	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—BDNF—endogenous depression	0.00146	0.00297	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—CYP2D6—endogenous depression	0.00145	0.00295	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.00145	0.00294	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00144	0.00292	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ANK3—endogenous depression	0.00142	0.00289	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL10—endogenous depression	0.0014	0.00284	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—BDNF—endogenous depression	0.00138	0.0028	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.00134	0.00272	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CACNB2—endogenous depression	0.00131	0.00267	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—WASF2—endogenous depression	0.0013	0.00265	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—NR3C1—endogenous depression	0.00129	0.00262	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—WASF1—endogenous depression	0.00125	0.00254	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—endogenous depression	0.00124	0.00253	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—WASF2—endogenous depression	0.00124	0.00251	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR2A—endogenous depression	0.00124	0.00251	CbGpPWpGaD
Thalidomide—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—endogenous depression	0.00123	0.00251	CbGpPWpGaD
Thalidomide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—endogenous depression	0.00123	0.0025	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2D6—endogenous depression	0.00123	0.00249	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CACNA1C—endogenous depression	0.0012	0.00244	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.00119	0.00241	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—WASF1—endogenous depression	0.00119	0.00241	CbGpPWpGaD
Thalidomide—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—endogenous depression	0.00116	0.00236	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—BDNF—endogenous depression	0.00113	0.0023	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—COMT—endogenous depression	0.0011	0.00223	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—MAOA—endogenous depression	0.00109	0.00222	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—CYP2D6—endogenous depression	0.00108	0.0022	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—CYP2D6—endogenous depression	0.00108	0.0022	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.00108	0.00219	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—CYP2D6—endogenous depression	0.00107	0.00217	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—CYP2D6—endogenous depression	0.00107	0.00217	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—CYP2D6—endogenous depression	0.00102	0.00208	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—CYP2D6—endogenous depression	0.00101	0.00205	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CACNB2—endogenous depression	0.001	0.00203	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.001	0.00203	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.000998	0.00203	CbGpPWpGaD
Thalidomide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—endogenous depression	0.000952	0.00193	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.000943	0.00192	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—endogenous depression	0.000923	0.00188	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CACNA1C—endogenous depression	0.000916	0.00186	CbGpPWpGaD
Thalidomide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—endogenous depression	0.000868	0.00176	CbGpPWpGaD
Thalidomide—CYP1A2—Phase II conjugation—COMT—endogenous depression	0.000844	0.00172	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—CYP2D6—endogenous depression	0.000837	0.0017	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—CYP2D6—endogenous depression	0.000825	0.00168	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—COMT—endogenous depression	0.000822	0.00167	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—COMT—endogenous depression	0.00082	0.00167	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—MAOA—endogenous depression	0.000816	0.00166	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—MAOA—endogenous depression	0.000814	0.00165	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—COMT—endogenous depression	0.000811	0.00165	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—COMT—endogenous depression	0.000809	0.00164	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—COMT—endogenous depression	0.000775	0.00157	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.000772	0.00157	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—MAOA—endogenous depression	0.000769	0.00156	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—endogenous depression	0.000769	0.00156	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—COMT—endogenous depression	0.000764	0.00155	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—CYP2D6—endogenous depression	0.000763	0.00155	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF2—endogenous depression	0.000759	0.00154	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—CYP2D6—endogenous depression	0.000752	0.00153	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—endogenous depression	0.000742	0.00151	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF1—endogenous depression	0.000728	0.00148	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF2—endogenous depression	0.00072	0.00146	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—POMC—endogenous depression	0.000711	0.00144	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.000704	0.00143	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF1—endogenous depression	0.00069	0.0014	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP2D6—endogenous depression	0.000652	0.00132	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP2D6—endogenous depression	0.000643	0.00131	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—COMT—endogenous depression	0.000634	0.00129	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—MAOA—endogenous depression	0.00063	0.00128	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—COMT—endogenous depression	0.000625	0.00127	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—endogenous depression	0.000601	0.00122	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—COMT—endogenous depression	0.000578	0.00117	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—MAOA—endogenous depression	0.000574	0.00117	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—COMT—endogenous depression	0.00057	0.00116	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—POMC—endogenous depression	0.000531	0.00108	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—POMC—endogenous depression	0.00053	0.00108	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—POMC—endogenous depression	0.000501	0.00102	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—COMT—endogenous depression	0.000494	0.001	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF2—endogenous depression	0.000491	0.000997	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—MAOA—endogenous depression	0.000491	0.000996	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—COMT—endogenous depression	0.000487	0.00099	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF1—endogenous depression	0.00047	0.000955	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF2—endogenous depression	0.000466	0.000946	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADM—endogenous depression	0.000449	0.000911	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF1—endogenous depression	0.000446	0.000906	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADM—endogenous depression	0.000426	0.000865	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—POMC—endogenous depression	0.00041	0.000833	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TPH1—endogenous depression	0.00041	0.000832	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CRH—endogenous depression	0.000376	0.000764	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—OXT—endogenous depression	0.000376	0.000764	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—POMC—endogenous depression	0.000374	0.000759	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR1A—endogenous depression	0.000362	0.000735	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CRH—endogenous depression	0.000357	0.000725	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—OXT—endogenous depression	0.000357	0.000725	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2C—endogenous depression	0.00035	0.00071	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR1A—endogenous depression	0.000343	0.000698	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2C—endogenous depression	0.000332	0.000674	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPH1—endogenous depression	0.000325	0.00066	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—POMC—endogenous depression	0.000319	0.000649	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TPH2—endogenous depression	0.00031	0.00063	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CACNB2—endogenous depression	0.00031	0.00063	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR7—endogenous depression	0.000306	0.000622	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPH1—endogenous depression	0.000306	0.000622	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPH1—endogenous depression	0.000305	0.00062	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—DPYD—endogenous depression	0.000305	0.00062	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR7—endogenous depression	0.000291	0.00059	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPH1—endogenous depression	0.000289	0.000586	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CACNA1C—endogenous depression	0.000284	0.000577	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—endogenous depression	0.000273	0.000554	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP2D6—endogenous depression	0.000248	0.000504	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPH2—endogenous depression	0.000246	0.000501	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CACNB2—endogenous depression	0.000246	0.000501	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DPYD—endogenous depression	0.000242	0.000492	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPH1—endogenous depression	0.000236	0.00048	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPH2—endogenous depression	0.000232	0.000471	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNB2—endogenous depression	0.000232	0.000471	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPH2—endogenous depression	0.000231	0.00047	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNB2—endogenous depression	0.000231	0.00047	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DPYD—endogenous depression	0.000228	0.000464	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DPYD—endogenous depression	0.000228	0.000463	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CACNA1C—endogenous depression	0.000225	0.000458	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPH2—endogenous depression	0.000219	0.000444	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNB2—endogenous depression	0.000219	0.000444	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—endogenous depression	0.000217	0.00044	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPH1—endogenous depression	0.000215	0.000437	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DPYD—endogenous depression	0.000215	0.000437	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—endogenous depression	0.000214	0.000436	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNA1C—endogenous depression	0.000212	0.000431	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNA1C—endogenous depression	0.000212	0.00043	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—endogenous depression	0.000203	0.000413	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNA1C—endogenous depression	0.0002	0.000406	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2D6—endogenous depression	0.000197	0.0004	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—endogenous depression	0.000192	0.000391	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—COMT—endogenous depression	0.000188	0.000382	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOA—endogenous depression	0.000187	0.000379	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2D6—endogenous depression	0.000185	0.000377	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2D6—endogenous depression	0.000185	0.000376	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPH1—endogenous depression	0.000184	0.000374	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPH2—endogenous depression	0.000179	0.000364	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNB2—endogenous depression	0.000179	0.000364	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DPYD—endogenous depression	0.000176	0.000358	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2D6—endogenous depression	0.000175	0.000355	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—endogenous depression	0.000171	0.000348	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNA1C—endogenous depression	0.000164	0.000332	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPH2—endogenous depression	0.000163	0.000331	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNB2—endogenous depression	0.000163	0.000331	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—endogenous depression	0.000163	0.00033	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—endogenous depression	0.000161	0.000326	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—endogenous depression	0.000157	0.00032	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—COMT—endogenous depression	0.000149	0.000303	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNA1C—endogenous depression	0.000149	0.000303	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOA—endogenous depression	0.000148	0.000301	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—endogenous depression	0.000144	0.000291	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2D6—endogenous depression	0.000143	0.000291	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—COMT—endogenous depression	0.000141	0.000285	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—COMT—endogenous depression	0.00014	0.000285	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOA—endogenous depression	0.00014	0.000283	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPH2—endogenous depression	0.000139	0.000283	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNB2—endogenous depression	0.000139	0.000283	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOA—endogenous depression	0.000139	0.000283	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—endogenous depression	0.000137	0.000279	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—COMT—endogenous depression	0.000133	0.000269	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOA—endogenous depression	0.000132	0.000267	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2D6—endogenous depression	0.00013	0.000265	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1C—endogenous depression	0.000128	0.000259	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—endogenous depression	0.000123	0.000249	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—endogenous depression	0.000122	0.000247	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2D6—endogenous depression	0.000111	0.000226	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—endogenous depression	0.000108	0.00022	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOA—endogenous depression	0.000108	0.000219	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—endogenous depression	9.89e-05	0.000201	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOA—endogenous depression	9.82e-05	0.000199	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—endogenous depression	9.65e-05	0.000196	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—endogenous depression	9.09e-05	0.000185	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—endogenous depression	9.07e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—endogenous depression	8.57e-05	0.000174	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—endogenous depression	8.45e-05	0.000172	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOA—endogenous depression	8.39e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—endogenous depression	7.01e-05	0.000142	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—endogenous depression	6.39e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—endogenous depression	5.46e-05	0.000111	CbGpPWpGaD
